BRAF and melanoma: An open-label phase I trial examined the intratumoral injection of a non-neurovirulent rhinovirus:poliovirus chimera (PVSRIPO) in patients with refractory melanoma stage IIIB-IV that showed disease progression on anti-PD-1 and BRAF/MEK inhibitors, if BRAF mutant.